Modality
Multispecific
MOA
HPK1i
Target
MALT1
Pathway
Neuroinflam
BCC
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
~Nov 2018
→ ~Feb 2020
NDA/BLA
May 2020
→ Dec 2031
NDA/BLACurrent
NCT05917680
1,082 pts·BCC
2025-09→2029-02·Completed
NCT03952605
1,273 pts·BCC
2020-05→2031-12·Active
2,355 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-172.9y awayPh3 Readout· BCC
2031-12-235.7y awayPh3 Readout· BCC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2029-02-17 · 2.9y away
BCC
Ph3 Readout
2031-12-23 · 5.7y away
BCC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05917680 | NDA/BLA | BCC | Completed | 1082 | PANSS |
| NCT03952605 | NDA/BLA | BCC | Active | 1273 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |